Phenotypes Associated with This Genotype

Genotype
MGI:5906908

• Allelic Composition: Stat3^tm1Vpo/Stat3^tm1Vpo; Tg(Myh6-cre)2182Mds/0
• Genetic Background: involves: 129P2/OlaHsd * FVB/N

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

pregnancy-related premature death ( J:141591 )

• about 2/3 of females die after the second pregnancy

• no females survive more than 5 pregnancies

• death always occurs within the first 3 weeks after delivery

cardiovascular system

abnormal angiogenesis ( J:141591 )

• myocardial angiogenesis is impaired in postpartum females, with mice showing reduced left ventricle capillary density postpartum compared to controls

abnormal myocardial fiber morphology ( J:141591 )

• increase in cardiomyocyte length in postpartum females

cardiac fibrosis ( J:141591 )

• extensive cardiac fibrosis in postpartum females

dilated heart ( J:141591 )

• 4-chamber dilatation in postpartum females

dilated heart left ventricle ( J:141591 )

decreased cardiac muscle contractility ( J:141591 )

• depressed fractional shorting in postpartum females

abnormal heart echocardiography feature ( J:141591 )

• echocardiography indicates left ventricular dilatation and depressed fractional shorting in postpartum females

increased cardiomyocyte apoptosis ( J:141591 )

• cardiac apoptosis is increased in postpartum females

cardiomyopathy ( J:141591 )

• all females develop postpartum cardiomyopathy

• treatment with tetrakis (4-benzoic acid) porphyrin (MnTBAP), a pharmacological suppressor of ROS, partially suppresses postpartum cardiomyopathy

• treatment with bromocriptine, a dopamine-D2-receptor agonist and inhibitor of prolactin secretion, prevents postpartum cardiomyopathy and mortality in females

congestive heart failure ( J:141591 )

• after 2 pregnancies, the majority of females show signs of overt heart failure such as generalized edema and labored breathing

cellular

increased cardiomyocyte apoptosis ( J:141591 )

• cardiac apoptosis is increased in postpartum females

oxidative stress ( J:141591 )

• hearts of postpartum females exhibit increased oxidative stress

homeostasis/metabolism

abnormal atrial thrombosis ( J:141591 )

• thrombi are often seen in the atria of postpartum females

generalized edema ( J:141591 )

• females exhibit generalized edema after 2 pregnancies

muscle

abnormal myocardial fiber morphology ( J:141591 )

• increase in cardiomyocyte length in postpartum females

decreased cardiac muscle contractility ( J:141591 )

• depressed fractional shorting in postpartum females

increased cardiomyocyte apoptosis ( J:141591 )

• cardiac apoptosis is increased in postpartum females

cardiomyopathy ( J:141591 )

• all females develop postpartum cardiomyopathy

• treatment with tetrakis (4-benzoic acid) porphyrin (MnTBAP), a pharmacological suppressor of ROS, partially suppresses postpartum cardiomyopathy

• treatment with bromocriptine, a dopamine-D2-receptor agonist and inhibitor of prolactin secretion, prevents postpartum cardiomyopathy and mortality in females

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
peripartum cardiomyopathy		DOID:9997		J:141591